- Home
- SID vs IMCR Comparison
SID vs IMCR Comparison
Compare SID & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SID
- IMCR
- Stock Information
- Founded
- SID 1941
- IMCR 2008
- Country
- SID Brazil
- IMCR United Kingdom
- Employees
- SID N/A
- IMCR N/A
- Industry
- SID Steel/Iron Ore
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SID Industrials
- IMCR Health Care
- Exchange
- SID Nasdaq
- IMCR Nasdaq
- Market Cap
- SID 1.9B
- IMCR 1.7B
- IPO Year
- SID 1997
- IMCR 2021
- Fundamental
- Price
- SID $1.42
- IMCR $36.22
- Analyst Decision
- SID Strong Sell
- IMCR Buy
- Analyst Count
- SID 1
- IMCR 10
- Target Price
- SID $1.30
- IMCR $58.13
- AVG Volume (30 Days)
- SID 3.2M
- IMCR 286.3K
- Earning Date
- SID 07-31-2025
- IMCR 08-07-2025
- Dividend Yield
- SID 5.85%
- IMCR N/A
- EPS Growth
- SID N/A
- IMCR N/A
- EPS
- SID N/A
- IMCR N/A
- Revenue
- SID $7,828,045,151.00
- IMCR $333,581,000.00
- Revenue This Year
- SID $7.14
- IMCR $26.82
- Revenue Next Year
- SID $3.79
- IMCR $8.15
- P/E Ratio
- SID N/A
- IMCR N/A
- Revenue Growth
- SID 2.40
- IMCR 25.75
- 52 Week Low
- SID $1.27
- IMCR $23.15
- 52 Week High
- SID $2.50
- IMCR $40.88
- Technical
- Relative Strength Index (RSI)
- SID 44.08
- IMCR 64.59
- Support Level
- SID $1.42
- IMCR $32.20
- Resistance Level
- SID $1.47
- IMCR $36.36
- Average True Range (ATR)
- SID 0.05
- IMCR 1.18
- MACD
- SID -0.00
- IMCR 0.33
- Stochastic Oscillator
- SID 35.20
- IMCR 96.88
About SID Companhia Siderurgica Nacional S.A.
Companhia Siderurgica Nacional is an integrated steel producer. together with its subsidiaries operates in five main business segments: Steel industry: production and marketing of flat and long steels; Mining: extraction, processing and marketing of iron ore, tin, limestone and dolomite; Cement: production and commercialization of bagged and bulk cement, in addition to aggregates, concrete, and other related products; Energy: generation and sale of energy from almost all renewable sources; and Logistics: participations in railways and port terminals. The group generates the majority of its revenue from the Steel industry segment. Geographically, it derives a majority of revenue from Asia.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.